Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?
Reitz
André
A
Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland. areitz@balgrist.unizh.ch
Müntener
Michael
M
Haferkamp
Axel
A
Hohenfellner
Markus
M
Schurch
Brigitte
B
D006152:Cyclic GMP / Q000378:metabolism*; D006801:Humans; D008297:Male; D009126:Muscle Relaxation / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000378:metabolism; D001748:Urinary Bladder Neck Obstruction / Q000378:metabolism / Q000517:prevention & control*
D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide; D006152:Cyclic GMP